Abeona Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Abeona Therapeutics (ABEO).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$20Upside to Avg. PT+350.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 18, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$28→$30
Sep 17, 2026	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$17
Aug 14, 2026	Oppenheimer	Jeff Jones	PT Cut	Outperform	$22→$21
May 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Mar 19, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Mar 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Oct 13, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Aug 18, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Aug 15, 2025	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$19→$20
Jul 16, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Jul 14, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Jun 2, 2025	Oppenheimer	Andreas Argyrides	Assumes	Outperform	$19
May 16, 2025	Stifel	Dae Gon Ha	PT Cut	Buy	$21→$20
Apr 30, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$15→$20
Mar 24, 2025	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$15
Mar 5, 2025	Oppenheimer	Francois Brisebois	Initiate	Outperform	$16
Feb 19, 2025	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$15
Nov 25, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$15
Oct 31, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$15
Oct 29, 2024	Cantor Fitzgerald	Kristen Kluska	Maintained	Overweight	$18

Analyst Ratings News

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.

Avi Kapoor

PRO
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $28 to $30.

Benzinga Newsdesk

PRO
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.

Benzinga Newsdesk

Abeona Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Abeona Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

PRO
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRO
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PRO
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

People Also Watch

People Also Watch

Abeona Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Abeona Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday

PROCantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRORoth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PROOppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PROHC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

PROHC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

PRO
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

PRO
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target